Fig. 2
From: Antiviral activity of silver nanoparticles against H1N1 influenza virus
a MDCK cells infected with influenza A virus/H1N1 at an MOI of 0.1 were treated in triplicate with different concentrations (0.005, 0.01, 0.05, 0.1, 0.5 mg/mL) of oseltamivir. Oseltamivir demonstrated a significant inhibitory effect on influenza A virus/H1N1 replication compared to the control group, as indicated by differences in CCID50. b Impact of oseltamivir at different concentrations (0.005, 0.01, 0.05, 0.1, 0.5 mg/mL) on the growth of influenza A/H1N1 virus following virus inoculation (MOI: 0.1) into MDCK cells. The influenza A virus (H1N1) titer decreased from 53 HAU/50 µL in the control group to zero, consistently maintained at zero in subsequent samples, demonstrating oseltamivir's inhibitory effect on virus growth. c MDCK cells infected with influenza A virus/H1N1 at an MOI of 0.1 were treated in triplicate with different concentrations (0.005, 0.01, 0.05, 0.1, 0.5 mg/mL) of oseltamivir. Real-Time PCR analysis revealed higher viral genome copies in the control group compared to the experimental group. Oseltamivir reduced influenza A virus (H1N1) titers at all tested concentrations. Statistical significance was determined at p < 0.05 for all tests